TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Prenetics Group ( (PRE) ) is now available.
On November 19, 2025, Prenetics Global Limited’s CEO and co-founder, Danny Sheng Wu Yeung, purchased 20,000 shares of the company’s Class A Ordinary Shares at $13.00 each, totaling $260,000. This acquisition increased his total holdings to 96,412 shares, potentially signaling confidence in the company’s future prospects.
The most recent analyst rating on (PRE) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The overall stock score of 42 reflects significant profitability and cash flow challenges, as well as bearish technical indicators. The company’s strong equity base provides some financial stability, but the negative P/E ratio and lack of dividend yield highlight ongoing financial struggles.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited is a leading health sciences company known for its IM8 premium health and longevity brand.
Average Trading Volume: 141,060
Technical Sentiment Signal: Buy
Current Market Cap: $179.3M
For an in-depth examination of PRE stock, go to TipRanks’ Overview page.